Aligos Therapeutics Overview
Compare Aligos Therapeutics's DCF valuation ($-0.38) to today's market price.
Get informed when a big investor buys or sells
+ Follow$-0.38
Overvalued by 106.2% based on the discounted cash flow analysis.
The latest DCF fair value for ALGS is $-0.38. Investors often review this figure alongside Aligos Therapeutics's historical trend and sector peers before judging valuation or financial health.
A DCF fair value of $-0.38 for Aligos Therapeutics suggests the stock may be overvalued by roughly 106.2% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.
After noting ALGS's DCF fair value ($-0.38), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Aligos Therapeutics's DCF fair value against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
